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Abstract
Background Little is known about the ocular penetration of
echinocandin antifungals. We studied the ocular distribution
of systemically administered caspofungin in a rabbit uveitis
model.
Methods Caspofungin (1 mg/kg per day) was given
intravenously to rabbits as a single dose or as repeated
daily doses on 7 days starting 24 h after induction of
unilateral uveitis by intravitreal endotoxin injection. Cas-
pofungin concentrations were determined by high-perfor-
mance liquid chromatography in the cornea, aqueous
humor, vitreous humor, and serum 4, 8, 16, and 24 h after
administration of a single dose and 24 h after the last of
seven doses.
Results The mean caspofungin concentration in the aque-
ous of the inflamed eye 4 and 8 h after single-dose
administration was 1.30±0.39 μg/ml and 1.12±0.34
μg/ml, respectively. Drug concentrations decreased to
0.24±0.09 μg/ml at 16 h and 0.26±0.14 μg/ml at 24 h.
In the vitreous of inflamed eyes drug levels were
undetectable at all time points. No drug was found in the
aqueous of inflamed eyes 24 h after the last of seven
repeated doses, and the vitreous only contained trace
amounts. In the corneas of inflamed eyes concentrations
reached 1.64±0.48 μg/g at 4 h, peaked at 2.16±1.14 μg/g
at 8 h, and declined to 1.87±0.52 μg/g and 1.49±0.48 μg/g
at 16 and 24 h, respectively. After repeated dosing, corneal
concentrations of caspofungin were 0.8 and 1.0 μg/g and
below the limit of detection in two of four animals. In non-
inflamed eyes no drug was detectable in the aqueous and
vitreous humor, and the corneas at any time point.
Conclusions In our model, caspofungin reached therapeu-
tically relevant levels in the aqueous and cornea but not in
the vitreous humor of inflamed eyes. Intraocular drug
deposition was critically dependent on a disrupted blood-
eye barrier. These findings suggest a limited role for
caspofungin in the treatment of fungal endophthalmitis.
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Introduction
Caspofungin is a first-in-class echinocandin with potent
antifungal activity against Candida and Aspergillus spp.,
the dominant human fungal pathogens. In vitro and in vivo
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caspofungin is fungicidal against nearly all Candida spp.
including fluconazole-resistant strains. Randomized clinical
trials with caspofungin in patients with candidemia,
invasive candidiasis, and Candida esophagitis demonstrate
equivalent efficacy to amphotericin B (AmB), with sub-
stantially fewer toxic effects [1, 5, 16, 24]. In addition,
caspofungin is as effective as liposomal AmB in the
empiric antifungal treatment of neutropenic patients with
persistent fever and has been licensed for the treatment of
severe pulmonary aspergillosis in patients who fail to
respond or are intolerant to therapy with AmB [26].
Fungal infections of the eyes are important causes of
morbidity and blindness; certain ophthalmic mycoses may
even be life-threatening [14, 28]. Keratitis is the most
frequent manifestation [20], but intraocular structures as
well as orbit, lids, lacrimal apparatus, conjunctiva, and
sclera may also be infected.
A recently published case series suggests that caspofun-
gin in combination with voriconazole may be useful for the
treatment of endogenous Candida endophthalmitis [2]. The
same drug combination has been used to successfully treat
a patient with endophthalmitis due to Aspergillus fumigatus
[6]. Clinical reports on the utility of caspofungin mono-
therapy for ocular infections are scarce and conflicting.
Cure has been reported for a patient with endogenous
Candida glabrata endophthalmitis presenting with a single
retinal lesion and mild retinitis [18]. In another reported
case of an ocular yeast infection, a patient with more
advanced endogenous endophthalmitis due to C. albicans
failed to respond to caspofungin. After 9 days of treatment
with standard doses, his intravitreal caspofungin level was
undetectable by a sensitive assay [8]. Successful treatment
with caspofungin has also been reported in a patient with
Acremonium endophthalmitis that failed to respond to AmB
[4]. In a rabbit model, topical caspofungin was as effective
as AmB for the treatment of Candida keratitis [9].
Caspofungin concentrations in homogenates of whole
non-inflamed rat eyes 0.5 and 24 h after a 2.0-mg/kg i.v.
bolus injection of radioactively labeled drug were 0.52 and
0.30 μg Eq/g, respectively [23]. Due to its high molecular
weight (1,213 kD) caspofungin may not cross the unin-
flamed blood-eye barrier that is thought to be impermeable
for molecules exceeding 500 kD. Indeed, the degree of
rupture of the blood-eye barrier in inflammation may be
critical for the intraocular deposition of this and other
echinocandins.
Only detailed knowledge of the pharmacokinetics of
caspofungin in ocular inflammation will provide a base for
rational treatment decisions. The disposition of caspofungin
to various ocular compartments after systemic treatment is
unknown. The aim of this study was to characterize the
ocular distribution of intravenously administered caspofun-
gin in a rabbit uveitis model. For that purpose, high-
performance liquid chromatography (HPLC) assays for the
determination of caspofungin concentrations in the cornea,




Twenty adult (nine male) Burgundy fawn rabbits (2.3–
4.9 kg) were used in this study. They were provided by an
authorized breeding center and were kept in individual
cages under well-defined and standardized conditions (in a
humidity and temperature controlled room, with a cycle of
13 h of light and 11 h of dark). They received standard dry
food and water ad libitum. All eyes were initially examined
with a handheld slit lamp. Only animals without any signs
of ocular inflammation were included. All experiments
were conducted in accordance with the “Principles of
laboratory animal care” (NIH publication No. 85-23,
revised 1985), the OPRR Public Health Service Policy on
the Humane Care and Use of Laboratory Animals (revised
1986), and the US Animal Welfare Act, as amended, and
were approved by the Swiss Federal and local Ethics and
Agricultural Committees.
Anesthesia
Animals were anesthetized with intramuscular ketamine
(35 mg/kg of body weight; Ketalar, Parke-Davis, Ann
Arbor, MI, USA) and xylazine (5 mg/kg; Xylapan,
Chassot, Bern, Switzerland). Novocaine 0.2% (Inselspital
Pharmacy, Bern, Switzerland) eye drops were used for
topical anesthesia. All rabbits were anesthetized once for
the induction of uveitis and placement of the central venous
catheter. This vascular access was established by surgical
placement of a subcutaneous silastic central venous catheter
that permitted one-time or repeated drug administrations
without further anesthesia [25].
Induction of experimental uveitis
After washing the ocular surface with sterile novocaine
0.2%, 100 ng (for animals given a single drug dose) or
50 μg (for animals given multiple drug doses) of
lipopolysaccharide (LPS) from Escherichia coli (Sigma,
St. Louis, MO, USA) diluted in 10 μl of sterile saline
solution were injected [13]. The higher LPS dose was
administered to maintain intraocular inflammation over the
treatment period [7]. LPS was injected through the sclera
into the vitreous using a 30–1/2 G needle connected to a
Hamilton syringe. The injection was performed in the right
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eye of each animal, taking care to avoid damage to the lens.
The left eyes served as controls. Inflammation was
evaluated by clinical observation of iris and conjunctival
hyperemia.
Single-dose studies
Single-dose kinetics of caspofungin acetate (Cancidas,
Merck, Whitehouse Station, NJ, USA) were studied over
24 h. Immediately before use, caspofungin acetate was
dissolved in sterile 0.9% sodium chloride to a concentration
of 0.5 mg/ml. Twenty-four hours after induction of uveitis,
16 rabbits were given 1 mg/kg caspofungin over 6 min by
steady bolus injection via a central venous catheter. The
drug dosage used corresponds to the standard dose
recommended for the treatment of human fungal infections
and is well tolerated by rabbits. Four animals per time point
were sacrificed by cervical dislocation and subsequent
exsanguination at 4, 8, 16, and 24 h after drug administra-
tion. Blood samples were collected during bleeding, and
serum was separated by centrifugation. Aqueous humor
was drawn from the freshly enucleated eyes with a
tuberculin syringe using a 30-gauge needle. The cornea
was excised at the limbus. After sectioning the eyes just
behind the lens, vitreous humor was obtained by dissecting
it carefully from the retina.
Multiple-dose study
Twenty-four hours after induction of uveitis, four rabbits
were given doses of 1 mg/kg caspofungin by steady
intravenous bolus via a central venous catheter that were
repeated daily for 7 consecutive days (total seven doses).
Twenty-four hours after the last dose, the rabbits were
sacrificed and samples were prepared for examination as
described above.
Analytical procedures
Samples were stored at −70°C until analysis. Blank
aqueous humor, blank vitreous humor, and blank corneas
were obtained from porcine eyes collected at the abattoir.
Blank plasma was prepared from bovine blood. Caspofun-
gin acetate was a kind gift of D. Sanglard, Institute of
Microbiology, University of Lausanne, Lausanne, Switzer-
land, and 4-hexylresorcinol (internal standard) was from
Fluka (Buchs, Switzerland). Chemicals used were of
analytical or HPLC grade. Caspofungin in serum and
plasma was extracted using Sep-Pak C18 extraction
cartridges (Waters, Milford, MA, USA) conditioned with
1 ml of methanol and 2 ml of distilled water. Two hundred
and fifty μl of serum or plasma mixed with 25 μl of a
12.5 μg/ml internal standard solution and 750 μl of water
was centrifuged at 14,000 g for 2 min and applied to the
cartridge. After rinsing with 2 ml water, the sample was
eluted with 1 ml of methanol containing 4% concentrated
acetic acid, evaporated to dryness at 40°C under a gentle
stream of air, and reconstituted in 225 μl of mobile phase.
For analysis of aqueous humor, 100 μl of sample and 20 μl
of a 1.25 μg/ml internal standard solution were mixed with
200 μl of methanol containing 4% acetic acid. After
centrifugation and evaporation, it was reconstituted in
100 μl of mobile phase prior to ultrasonic mixing
(Bransonic 92, Bender & Hobein, Zurich, Switzerland) for
5 min, and in case of turbid samples, centrifugation at
14,000 g for 1 min. Vitreous samples were homogenized
with an Ultra-Turrax microhomogenizer (IKA-Labortech-
nik, Staufen, Switzerland) at high speed for 10 s; 125 μl of
vitreous, 25 μl of a 1.25 μg/ml internal standard solution,
and 250 μl of methanol containing 4% acetic acid were
mixed, centrifuged at 14,000 g for 1 min, and the clear
supernatant was evaporated and redissolved in 125 μl of
mobile phase. Pieces of cornea weighing 20–50 mg were
added to 100 μl of distilled water, vortex mixed, and
centrifuged at 14,000 g. The sample was cut into small
pieces with scissors, mixed with 20 μl of a 1.25 μg/ml
internal standard solution, sonicated for 15 min, diluted
with 200 μl of methanol containing 4% acetic acid, and
centrifuged. The supernatant was evaporated and reconsti-
tuted with 100 μl of mobile phase. Recoveries for
caspofungin in serum, aqueous, vitreous, and cornea were
determined to be approximately 65, 86, 91, and 87%,
respectively.
Drug levels were determined as total caspofungin
concentrations by HPLC with fluorescence detection using
a protocol adapted from [19]. Briefly, an LC-Module I plus
autosampler and pump (Waters, Milford, MA, USA) were
connected to an LC 304 fluorescence detector (Linear
Instruments, Reno, NV, USA). A 250/8/4.6 Nucleosil 300
wide bore C8 column (Macherey-Nagel, Düren, Germany)
packed with 5 micron material was used. The mobile phase
comprised two solutions (A and B) that were mixed in a
volume/volume ratio (v/v) of 62:38 for vitreous and
aqueous and a ratio of 60:40 (v/v) for serum and cornea.
Solvent A was 0.1% trifluoroacetic acid (adjusted to pH 3
with diethylamine) and solvent B was acetonitrile. After a
run time of 11 min, the column was washed for 4 min with
a solution containing solvents A and B in a ratio (v/v) of
50:50 and reequilibrated for 5 min with mobile phase.
Elution was performed at a flow rate of 1.4 ml/min for
vitreous and aqueous, 1.3 ml/min for cornea, and 1.0
ml/min for serum. The column temperature was maintained
at 30°C. Excitation and emission wavelengths were set at
224 and 300 nm, respectively. For all assays, 50 μl of
sample was injected. The concentrations of the lowest
calibrators, i.e., 0.1 μg/ml for serum, 0.05 μg/ml for
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aqueous and vitreous, and 0.025 μg for cornea (for 40 mg
cornea: 0.625 μg/g cornea), were taken as quantification
limits. Intraday variabilities (n=4) were <7% in all cases.
All control samples were stable during the 3-month study
period and interday variabilities were below 10% for
plasma, aqueous, and vitreous, and below 20% for cornea.
Typical electropherograms obtained with aqueous humor
are presented in Fig. 1.
Results
Aqueous
To study drug penetration into the aqueous of inflamed and
uninflamed control eyes, samples harvested immediately
postmortem from eyes with iatrogenic uveitis leading to
disruption of blood-eye barriers were analyzed for caspo-
fungin concentration. Results were compared to those
obtained from similarly harvested aqueous from contralat-
eral, uninflamed eyes with intact blood-eye barriers.
Four and 8 h after intravenous injection of a single dose
of 1 mg/kg caspofungin, the mean drug concentration in the
aqueous of the inflamed eye was 1.30±0.39 and 1.12±
0.34 μg/ml, respectively. These concentrations are in excess
of the minimum inhibitory concentration of most Candida
and Aspergillus spp. Sixteen and 24 h after treatment, the
concentration decreased to 0.24±0.09 and 0.26±0.14 μg/ml,
respectively (Fig. 2a). Caspofungin was undetectable in the
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Fig. 1 Typical chromatograms
of caspofungin (CAS). a Blank
porcine aqueous fortified with
internal standard (IST). b Four-
fold diluted aqueous of an in-
flamed rabbit eye harvested 4 h
after a single-dose injection
containing 1.30 μg/ml caspo-
fungin. c Aqueous of a non-
inflamed eye obtained 8 h after a
single dose of caspofungin. d
Porcine aqueous spiked with
caspofungin at a concentration
of 0.5 μg/ml
Fig. 2 a–c Mean (±SD) caspofungin concentration over time in a
aqueous, b corneas of LPS-treated eyes, and c serum of rabbits
given a single intravenous dose of caspofungin at 1 mg/kg of body
weight (n=4 per time point)
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In the multiple-dose study animals were treated with
repeated daily doses of 1 mg/kg of body weight for 7 days.
Caspofungin concentration was below the level of deter-
mination in all the aqueous samples of inflamed and
control eyes collected 24 h after the last of seven doses
(Fig. 3).
Vitreous
After single-dose administration of 1 mg/kg caspofungin,
drug concentrations in all the vitreous samples from both
inflamed and non-inflamed eyes were below the level of
detection (0.05 μg/ml). Twenty-four hours after the last of
seven intravenous doses, caspofungin levels were undetect-
able in all vitreous samples with one exception: in one
inflamed eye a caspofungin concentration of 0.08 μg/ml
was found (Fig. 3).
Cornea
Topical antifungals are the treatment of choice for fungal
keratitis because high drug concentrations can be achieved
in the cornea, particularly when the corneal epithelium is
damaged, and systemic toxicity is minimal. In advanced
infections with threatening penetration into the anterior
chamber, however, systemic antifungals are often added.
We were therefore interested in determining the corneal
penetration of intravenous caspofungin. Four hours after
single-dose treatment, the mean caspofungin concentration
in the cornea of inflamed eyes was 1.64±0.48 μg/g.
Corneal drug concentrations also exceeded aqueous levels
after 8, 16, and 24 h at 2.16±1.14, 1.87± 0.52, and 1.49±
0.48 μg/g, respectively (Fig. 2b). Caspofungin levels in the
corneas of uninflamed eyes were undetectable at all time
points, suggesting that disruption of the blood-eye barriers
was critical for corneal drug deposition.
Corneal drug concentrations in inflamed eyes of rabbits
treated with multiple doses were 0.82 μg/g, and 1.03 μg/g
in two animals, and undetectable in the other two (Fig. 3).
Caspofungin was below the level of detection (0.625 μg/g)
in uninflamed eyes after repeated daily dosing.
Serum
Four hours after single-dose administration of caspofungin,
the mean drug concentration in serum was 1.91±0.46
μg/ml (Fig. 2c). It fell to 0.47±0.11, 0.08±0.01, and 0.03
±0.01 μg/ml after 8, 16, and 24 h, respectively. Serum
level 24 h after the last of seven daily caspofungin doses
was 0.17±0.06 μg/ml (Fig. 3)
Discussion
Despite treatment, fungal endophthalmitis results in loss of
useful vision in a majority of patients. New antifungal
drugs with good ocular penetration would be a welcome
addition to our therapeutic armamentarium. In spite of its
established efficacy for the treatment of a broad range of
infections due to Candida and Aspergillus spp., caspofun-
gin has only rarely been used to treat fungal infections of
the eyes and no clinical studies have been done [1, 16, 24].
In this study we aimed to characterize the penetration into
various ocular compartments of systemically administered
caspofungin in a rabbit uveitis model. For that purpose,
adequate assays had to be at hand. Several HPLC assays for
the measurement of caspofungin concentrations in plasma,
urine, and various tissues have been described in the literature
[3, 11, 12, 17, 19]. No assay for the determination of
caspofungin in ocular tissues has been found. The HPLC
method of Schwartz et al. [19] was adapted to quantify














































Fig. 3 Mean (+SD) caspofun-
gin concentrations in aqueous,
vitreous, and corneas of in-
flamed eyes as well as serum
after repeated-dose administra-
tion. Samples were taken 24 h
after the last of seven daily
doses of 1 mg/kg caspofungin
administered via a central ve-
nous catheter (n= 4). Drug lev-
els were undetectable in the
aqueous and the vitreous
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serum/plasma. The assays, which were found to be sensitive
and robust, are all based upon the use of a C8 column and
mobile phases composed of an aqueous, 0.1% trifluoroacetic
acid solution at pH 3, and acetonitrile, but differ in sample
preparation. Solid phase extraction with C18 cartridges is
employed for serum analysis, whereas protein precipitation
with acidified methanol is used for the determination of
caspofungin in aqueous, vitreous, and cornea. The lower
limit of quantification (LLQ) of our assay for serum and
plasma was 0.1 μg/ml and was significantly lower for ocular
tissues. This compares favorably with the sensitivity of
published HPLC assays with LLQs for plasma of 0.15 μg/ml
[11] and 0.125 μg/ml [17]. In the paper by [19] a diol solid
phase extraction column was used to extract caspofungin
from human plasma and urine. In our laboratory, the use of
such a polar sorbent did not reveal any recovery for the
investigated cyclic hexapeptide. With a C18 cartridge,
however, a respectable recovery was obtained. Furthermore,
there was no difference between plasma and serum.
In inflamed eyes caspofungin concentrations exceeding
1 μg/ml were measured in the aqueous during the first 8 h
postdosing and in the cornea for 24 h after single-dose
administration. These concentrations exceed the minimal
inhibitory concentrations of most Candida and Aspergillus
spp. and are associated with relevant antifungal activity in
animal models [15].
Corneal concentrations in inflamed eyes substantially
exceeded both serum and aqueous levels: they peaked at
8 h and remained above 1.4 μg/ml for 24 h. The absence of
detectable drug levels from corneas of uninflamed eyes
suggests that disruption of the blood-eye barrier is as
critical for corneal penetration as for other ocular compart-
ments. The same observation also makes it improbable that
significant amounts of drug might have penetrated through
the tear film although drug concentrations in tears were not
established.
In murine models, the kidneys, liver, and large intestine
were found to have higher exposure levels to caspofungin than
plasma and serum [12, 15]. Differences in the extent of protein
binding may explain the high corneal drug concentrations we
found. Retention of the water-soluble caspofungin macromol-
ecule in the proteoglycans of the corneal stroma may be
another reason for corneal drug accumulation.
Caspofungin levels in the vitreous were undetectable in
all animals after single-dose administration and in all but
one after repeated dosing. Thus, even in the presence of a
disrupted blood-eye barrier caspofungin appears to poorly
penetrate into this compartment. A similar finding was
recently reported in a patient whose Candida albicans
endophthalmitis failed to respond to caspofungin. After
9 days of therapy, the level of caspofungin in the vitreous of
his infected eye was below 50 ng/ml while his blood level
at the time of vitrectomy was 3.3 μg/ml [8].
Using caspofungin at higher doses than currently
recommended might result in higher intraocular drug
deposition and possibly increased efficacy; reports on
paradoxical effects of increased caspofungin doses in
animal models, however, warrant caution with this ap-
proach [21, 22, 27].
The serum concentrations of caspofungin we measured
at 4 and 8 h postdosing are in good agreement with reported
results for rabbit plasma [11]. This is also true for the slight
drug accumulation we observed in serum following
administration over 7 days. Compared to serum drug levels
we found ocular caspofungin concentrations to decline
more slowly, an observation that is consistent with the
reported plasma pharmacokinetics of caspofungin that are
largely determined by tissue distribution [12].
The unilateral uveitis model we used allows for the
direct observation, in the same animal, of the influence on
drug disposition of a disrupted blood-eye barrier. With a
sensitive HPLC assay drug levels were undetectable in
aqueous, vitreous, and cornea of non-inflamed eyes. Our
findings suggest that caspofungin does not penetrate the
intact blood-eye barrier. This may be explained in part by
the drug’s high molecular weight and its level of protein
binding in serum of 96% [12].
Repeated dosing was not found to lead to higher
intraocular drug concentrations. On the contrary, caspofun-
gin levels were lower in both aqueous and cornea than at
the same interval after single-dose administration. This may
be due to a decreasing intensity of LPS-induced uveitis
over time in spite of the fact that higher endotoxin doses
were used in the multiple-dose study [10]. There is no
evidence that in the absence of fungal infection caspofungin
may directly influence the host’s immune response and thus
modulate the intensity of, e.g., iatrogenic uveitis.
In established fungal endophthalmitis the treatment of
choice is vitrectomy followed by local injection of an
antifungal agent, usually amphotericin B. In endogenous
endophthalmitis that results from hematogenous fungal
dissemination, additional systemic treatment is indicated.
In cases where vitrectomy must be postponed or where it
may be contraindicated, control of endophthalmitis must
rely on the local effects of systemically administered
antifungals [2]. The poor vitreal penetration of caspofungin
in our experimental system suggests it may be of limited
usefulness in the treatment of endogenous endophthalmitis
where hematogenously disseminated fungal elements reach
the vitreous first, after establishing infection in the choroid.
At present, the i.v. administration of an antifungal agent
is not standard for the treatment of fungal keratitis.
Nevertheless, many clinicians use adjuvant systemic treat-
ment to prevent spread into the anterior chamber and
progression to exogenous endophthalmitis. In this chal-
lenging clinical situation there might only be minimal
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intraocular inflammation. Because caspofungin only rea-
ches potentially therapeutic concentrations in cornea and
aqueous humor when the blood-eye barrier is disrupted, its
role as preemptive treatment in exogenous fungal endoph-
thalmitis may be equally limited.
Caution is warranted in extrapolating the results of this
rabbit model of iatrogenic uveitis to human fungal
endophthalmitis. While caspofungin has similar pharmaco-
kinetics in humans and rabbits and the rabbit model is of
established relevance for human eye diseases, the disrup-
tion of the blood-eye barrier resulting from endotoxin-
induced uveitis may differ from that found in fungal
endophthalmitis [17].
In summary, our model suggests that caspofungin ocular
penetration is critically dependent on disruption of the
blood-eye barrier. This may limit its usefulness in fungal
endophthalmitis. Studies in animals with fungal endoph-
thalmitis are needed to further evaluate the drug’s potential.
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